HIV-associated nephropathy

HIV-associated nephropathy (HIVAN) is the characteristic kidney disease caused by HIV infection itself: a collapsing form of focal glomerulosclerosis that can produce nephrotic syndrome and rapid loss of renal function. It must be distinguished from the immune-complex glomerular diseases that also occur in HIV-infected patients, including membranoproliferative glomerulonephritis, IgA nephropathy, membranous nephropathy, non-collapsing focal segmental glomerulosclerosis, and lupus-like glomerulonephritis. In patients also infected with HCV, cryoglobulinemic membranoproliferative glomerulonephritis is more plausibly attributed to HCV than to HIV, while the contribution of HCV to other HIV-related glomerular lesions remains uncertain.

Definition and Clinical Pattern

HIVAN is defined histologically by collapsing focal glomerulosclerosis, accompanied by striking podocyte hypertrophy and tubulointerstitial abnormalities. Clinically, it most often presents as nephrotic syndrome; without treatment, renal function deteriorates rapidly. The lesion is therefore not simply a laboratory association with HIV infection but a distinct clinicopathologic syndrome in which glomerular collapse and interstitial injury are tied to an aggressive course of kidney disease.

HIVAN has no single pathognomonic monopoly over the collapsing pattern. Similar collapsing focal glomerulosclerosis has been reported with other viral infections, cancers, drugs, and systemic diseases. The diagnosis consequently depends on integrating the renal biopsy with the patient’s HIV status and clinical presentation rather than treating the microscopic pattern alone as definitive.

Pathogenesis and Susceptibility

The evidence supports a direct pathogenic role for HIV. HIV-related antigens have been identified in glomerular cells in patients with HIVAN, and transgenic animal models show that expression of HIV genes is sufficient to promote glomerulosclerosis. This places the virus itself within the disease mechanism, rather than treating renal injury merely as an indirect consequence of systemic illness.

Host susceptibility is nevertheless decisive. Black patients infected with HIV are much more prone to developing HIVAN than patients of other ethnicities, and genetic predisposition appears crucial after HIV infection has occurred. The disease therefore emerges from an interaction between viral activity in the kidney and a susceptible host background, rather than from HIV exposure alone.

Distinction from Other HIV-Related Glomerular Disease

HIV-infected patients may develop several immune-complex glomerulonephritides in addition to HIVAN. These disorders do not show the racial predisposition characteristic of HIVAN, and their precise diagnosis generally requires renal biopsy. The biopsy is important not only for naming the lesion but also for estimating prognosis and selecting treatment in an individual patient.

HCV coinfection complicates this diagnostic field. Approximately 30% of HIV-infected patients are affected by HCV coinfection, and a large proportion of HIV patients with glomerular disease are also HCV infected. In reported cases of cryoglobulinemic membranoproliferative glomerulonephritis, HCV is likely to be the responsible agent. By contrast, its role in other HIV-associated glomerular diseases is not established. HCV-associated renal disease may include mixed cryoglobulinemia, in which kidney manifestations range from proteinuria and hematuria to nephritic or nephrotic syndrome, but those findings should not be conflated with HIVAN.

Treatment and Prognosis

Antiretroviral therapy has markedly changed the outlook for HIVAN. Early reports described a dismal prognosis, whereas subsequent cohort studies strongly suggest that antiretroviral treatment slows renal impairment and may even prevent HIVAN from developing. Although prospective controlled trials have not been performed, the consistency of these observational findings supports suppression of HIV replication as the central therapeutic strategy.

Blockade of the renin–angiotensin system provides an additional renal intervention. It has been shown to reduce proteinuria and slow progression of renal failure in affected patients. Together, antiretroviral therapy and renin–angiotensin-system blockade address both the presumed viral driver and an important pathway of glomerular injury.

The prognosis of glomerular disease in patients coinfected with HIV and HCV remains poor overall, particularly when the lesion is not HIVAN but an HCV-related immune-complex process. Some studies suggest that antiretroviral therapy can improve this otherwise unfavorable renal and patient survival, but information on disease-specific anti-HCV treatment and immunosuppressive therapy in coinfected patients remains limited.

Diagnostic and Clinical Significance

HIVAN illustrates why HIV-associated kidney disease cannot be reduced to a single test result. HCV diagnosis itself requires both anti-HCV antibodies and detectable HCV RNA to establish active chronic infection, while assessment of HCV-related renal involvement requires attention to cryoglobulinemia, complement abnormalities, proteinuria, hematuria, and renal function. In the transplant and chronic kidney disease settings, screening systems further distinguish antibody positivity, active viremia, and organ injury. These distinctions are essential when HIVAN, HCV-associated glomerulonephritis, and other causes of renal dysfunction coexist.

The concept also marks a shift from an initially bleak clinical picture toward a treatable virus-associated kidney disease. HIV can directly injure glomerular cells, but the resulting renal syndrome is shaped by host genetics, competing infections such as HCV, and access to effective antiretroviral care. Its significance lies precisely in that convergence: HIVAN is both a recognizable biopsy lesion and a model of how viral replication, inherited susceptibility, and therapeutic intervention determine the course of chronic kidney disease.